Genetic Signatures Ltd. (AU:GSS)
ASX:GSS
Want to see AU:GSS full AI Analyst Report?
GSS Stock Chart & Stats
AU$0.24
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.24
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.07 - AU$0.44
Previous CloseN/A
Volume34.30K
Average Volume (3M)149.45K
Market Cap
AU$17.72M
Enterprise Value-AU$864.42K
Total Cash (Recent Filing)AU$29.87M
Total Debt (Recent Filing)AU$653.00K
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Aug 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding227,138,820
10 Day Avg. Volume161,537
30 Day Avg. Volume149,454
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)1.65
Price to Sales (P/S)5.20
P/FCF Ratio-6.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.10Price Target Upside-58.33% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.08
Revenue Forecast (FY)AU$18.20M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueGenetic Signatures sells consumable PCR test kits where revenue recurs as labs run tests. That installed-base driven consumables model yields predictable, repeatable revenue streams over months, supporting durable top-line visibility and long-term customer stickiness.
Proprietary 3base Technology And Assay MenuThe proprietary 3base chemistry and broad multiplex assay menu create technical differentiation and higher value per sample. This fosters switching costs for labs, enables multi-pathogen panels, and supports sustainable product expansion across GI, respiratory and other panels.
Low Financial LeverageVery low debt gives the company financial flexibility to fund R&D, commercial expansion or absorb ongoing losses without significant interest burdens. A strong equity base reduces near-term solvency risk and supports strategic options over the coming months.
Bears Say
Persistent Negative ProfitabilityThe company has sustained negative net, EBIT and EBITDA margins, meaning operations currently destroy value. Unless cost structure, pricing or scale change materially, continued losses will impede reinvestment, long-term margin recovery and eventual path to durable profitability.
Negative Operating And Free Cash FlowNegative operating and free cash flows indicate ongoing cash burn from core operations. This forces reliance on external funding or equity issuance to sustain growth, creating dilution risk and constraining investments in commercialization or product development over the medium term.
Negative Return On EquityDespite a strong equity base, the company generates negative ROE, showing it currently cannot convert capital into profits. Persistent negative ROE signals poor capital efficiency and raises questions about long-term shareholder value creation absent a clear profitability turnaround.
Genetic Signatures Ltd. News
GSS FAQ
What was Genetic Signatures Ltd.’s price range in the past 12 months?
Genetic Signatures Ltd. lowest share price was AU$0.07 and its highest was AU$0.43 in the past 12 months.
What is Genetic Signatures Ltd.’s market cap?
Genetic Signatures Ltd.’s market cap is AU$17.72M.
When is Genetic Signatures Ltd.’s upcoming earnings report date?
Genetic Signatures Ltd.’s upcoming earnings report date is Aug 24, 2026 which is in 77 days.
How were Genetic Signatures Ltd.’s earnings last quarter?
Genetic Signatures Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.028 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.028.
Is Genetic Signatures Ltd. overvalued?
According to Wall Street analysts Genetic Signatures Ltd.’s price is currently Overvalued.
Does Genetic Signatures Ltd. pay dividends?
Genetic Signatures Ltd. does not currently pay dividends.
What is Genetic Signatures Ltd.’s EPS estimate?
Genetic Signatures Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genetic Signatures Ltd. have?
Genetic Signatures Ltd. has 227,138,820 shares outstanding.
What happened to Genetic Signatures Ltd.’s price movement after its last earnings report?
Genetic Signatures Ltd. reported an EPS of -AU$0.028 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -13.043%.
Which hedge fund is a major shareholder of Genetic Signatures Ltd.?
Currently, no hedge funds are holding shares in AU:GSS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genetic Signatures Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
AU$0.10 (-58.33% Downside)
AU$0.10 (-58.33% Downside)
Blogger Sentiment
Bullish
AU:GSS Sentiment 75%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.35%
12-Months-Change
Fundamentals
Return on Equity
-23.93%
Trailing 12-Months
Asset Growth
-16.90%
Trailing 12-Months
Company Description
Genetic Signatures Ltd.
Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. It designs and manufactures a suite of real-time polymerase chain reaction-based products for detection of infectious diseases under the EasyScreen brand name. The company also provides MDx 3Base platform technology that enables hospital and pathology laboratories to screen for a range of infectious pathogens. In addition, it offers detection kits for gastrointestinal infections, respiratory, sexual health, anti-microbial resistance, meningitis, and tropical disease. The company was incorporated in 2001 and is headquartered in Newtown, Australia.
GSS Stock 12 Month Forecast
Average Price Target
AU$0.10
▼(-58.33% Downside)
Technical Analysis
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Lumos Diagnostics Holdings Ltd.
―
Cryosite Limited
―
Inoviq Ltd
―